CMS 2012 Budget Looks To Biosimilars, Brand/Generic Deals To Offset Costs
Executive Summary
In its 2012 budget proposal for the Centers for Medicare and Medicaid Services, the Obama administration casts its net wide to find potential savings from prescription drug spending to help offset Medicare and Medicaid costs.
You may also be interested in...
Trump's Budget Request To Include ANDA Exclusivity Changes
180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.
Trump's Budget Request To Include ANDA Exclusivity Changes
180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.